4569 — Kyorin Pharmaceutical Co Share Price
Last trade - 00:00- ¥102bn
- ¥104bn
- ¥113bn
- 63
- 61
- 83
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.22 | ||
| PEG Ratio (f) | 1.85 | ||
| EPS Growth (f) | 10.26% | ||
| Dividend Yield (f) | 3.15% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.81 | ||
| Price to Tang. Book | 0.84 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.85 | ||
| EV to EBITDA | 12.9 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.92% | ||
| Return on Equity | 3.36% | ||
| Operating Margin | 3.2% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 113,620 | 109,983 | 102,904 | 105,534 | 113,270 | 120,100 | 121,900 | 0.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +15.03 | +1.67 | -17.47 | -17.56 | +6.08 | +20.45 | +10.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
Directors
- Minoru Hogawa CHM (66)
- Yutaka Ogihara PRE (54)
- Yoh Ito FID
- Michio Onota CEX (61)
- Shigeru Ogihara SMD (64)
- Yasuyuki Shimokawa DHR
- Hiroshi Hashizume EXO
- Morio Yanagishima EXO
- Koichiro Hagihara DRC (62)
- Masahide Sugibayashi DRC (63)
- Ken Shigematsu IND (72)
- Noriyuki Shikanai IND (73)
- Hiromi Watanabe IND (74)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 31st, 1958
- Public Since
- March 10th, 2006
- No. of Shareholders
- 12,856
- No. of Employees
- 2,138
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 57,448,812
- Address
- 15/16F, Ochanomizu Sorashiti, CHIYODA-KU, 101-8311
- Web
- https://www.kyorin-pharm.co.jp/
- Phone
- +81 335254700
- Auditors
- Ernst & Young ShinNihon LLC
Latest News for 4569
Upcoming Events for 4569
Full Year 2024 Kyorin Pharmaceutical Co Ltd Earnings Release
Kyorin Pharmaceutical Co Ltd Annual Shareholders Meeting
Q1 2025 Kyorin Pharmaceutical Co Ltd Earnings Release
Similar to 4569
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 19:13 UTC, shares in Kyorin Pharmaceutical Co are trading at ¥1,777. This share price information is delayed by 15 minutes.
Shares in Kyorin Pharmaceutical Co last closed at ¥1,777 and the price had moved by +2.66% over the past 365 days. In terms of relative price strength the Kyorin Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -22.74% over the past year.
The overall consensus recommendation for Kyorin Pharmaceutical Co is Sell. You can view the full broker recommendation list by unlocking its StockReport.
The Kyorin Pharmaceutical Co dividend yield is 2.93% based on the trailing twelve month period.
Last year, Kyorin Pharmaceutical Co paid a total dividend of ¥52, and it currently has a trailing dividend yield of 2.93%.Looking ahead, the next dividend pay date is 2024-06-01.
We do not have data on when Kyorin Pharmaceutical Co is to next pay dividends. The historic dividend yield on Kyorin Pharmaceutical Co shares is currently 2.93%.
To buy shares in Kyorin Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥1,777, shares in Kyorin Pharmaceutical Co had a market capitalisation of ¥102bn.
Here are the trading details for Kyorin Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4569
Based on an overall assessment of its quality, value and momentum Kyorin Pharmaceutical Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kyorin Pharmaceutical Co is ¥1,750. That is 1.52% below the last closing price of ¥1,777.
Analysts covering Kyorin Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥94 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kyorin Pharmaceutical Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -18.96%.
As of the last closing price of ¥1,777, shares in Kyorin Pharmaceutical Co were trading -0.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kyorin Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 17.22. The shares last closed at ¥1,777.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kyorin Pharmaceutical Co's management team is headed by:
- Minoru Hogawa - CHM
- Yutaka Ogihara - PRE
- Yoh Ito - FID
- Michio Onota - CEX
- Shigeru Ogihara - SMD
- Yasuyuki Shimokawa - DHR
- Hiroshi Hashizume - EXO
- Morio Yanagishima - EXO
- Koichiro Hagihara - DRC
- Masahide Sugibayashi - DRC
- Ken Shigematsu - IND
- Noriyuki Shikanai - IND
- Hiromi Watanabe - IND